WorldCat Identities

Van Raemdonck, Dirk

Overview
Works: 11 works in 11 publications in 2 languages and 16 library holdings
Roles: Contributor, Opponent, Other, Editor
Publication Timeline
.
Most widely held works by Dirk Van Raemdonck
Gastro-tracheal fistula - unusual and life threatening complication after esophagectomy for cancer: a case report by Jane E Nardella( )

1 edition published in 2009 in English and held by 2 WorldCat member libraries worldwide

BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators by Leanda Vengethasamy( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Intérêt du monoxyde de carbone comme marqueur non invasif des lésions d'ischémie-reperfusion de poumons reconditionnés ex vivo by Maxime Maignan( )

1 edition published in 2015 in French and held by 2 WorldCat member libraries worldwide

Rationnel : Le développement des techniques de reperfusion pulmonaire ex vivo (Ex vivo lung perfusion : EVLP) vise à réduire la pénurie d'organes disponibles pour la transplantation. Le monoxyde de carbone (CO) pourrait aider à la sélection des greffons en cours d'EVLP puisque sa production endogène est augmentée en situation d'ischémie reperfusion. Objectifs : Mettre au point une technique de mesure du CO exhalé (eCO) lors de l'EVLP et étudier ses variations en fonction des lésions d'ischémie reperfusion. Méthodes : À partir d'un modèle porcin d'EVLP et à l'aide d'un appareil de spectrométrie laser basé sur le principe d'une cavité résonnante (optical-feedback cavity-enhanced absorption spectroscopy : OF-CEAS), eCO était mesuré selon différents paramètres ventilatoires, en ambiances polluées par des gaz pauvres (< 0,015ppmv) ou riches (9ppmv) en CO et après perfusion d'un inhibiteur de l'hème oxygénase (SnPP). eCO était ensuite comparé après 30 min (J0) ou 24 h (J1) d'ischémie froide et sa valeur prédictive pour sélectionner des greffons était calculée.Résultats : La concentration d'eCO de poumons isolés était de 0,45 ± 0.19 ppmv. Les pics d'eCO se produisaient pendant la phase expiratoire. Ni les variations de fraction inspirée en oxygène, ni la pollution de l'air ambiant ne modifiaient eCO. Les concentrations d'eCO n'étaient pas différentes après perfusion de SnPP. eCO était plus élevé à J1 par rapport à J0 (1,35 ± 0,259 ppmv vs. 0,951 ± 0,313, p = 0,01) et était corrélé à un indice de perméabilité de la membrane alvéolo capillaire. La meilleure valeur seuil d'eCO déterminée à partir de la courbe ROC était 0,860 ppmv (sensibilité de 1 (0,31 - 1), spécificité de 0,44 (0,15 - 0,77), valeur prédictive positive de 0,37 (0,10 - 0,74), valeur prédictive négative de 1 (0,39 - 1)). Conclusions : La mesure d'eCO en condition d'EVLP est faisable. eCO est significativement augmenté lorsque les lésions d'ischémie reperfusion sont accrues mais eCO ne peut pas être utilisé de façon isolée pour sélectionner les greffons pulmonaires
Massive lung collapse with partial resolution after several years: a case report by Elke Govaere( )

1 edition published in 2005 in English and held by 2 WorldCat member libraries worldwide

Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients by Rozenn Quarck( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Postoperative left ventricular function in different types of pulmonary hypertension: a comparative study( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract OBJECTIVES Left ventricular dysfunction after pulmonary endarterectomy is well described. Left ventricular failure has only been described after lung transplantation for pulmonary arterial hypertension (PAH). We sought to identify factors that contribute to this failure and hypothesized that atrial septostomy before transplantation could prevent this complication. METHODS From our database, all bilateral lung transplants for PAH (n = 24) and all pulmonary endarterectomies, with a minimal reduction of 800 dyn⋅s⋅cm (n = 27), were selected. Perioperative demographic and echocardiographic data were analysed. RESULTS In patients with PAH, pulmonary hypertension was diagnosed at a significantly younger age, and time between diagnosis and surgery was significantly longer. Before surgery, right ventricular dimensions were significantly larger and left ventricular wall thicknesses were significantly smaller, but left ventricular diastolic dysfunction was similar. Surgery caused a significant decrease in right ventricular dimensions (less extensive after pulmonary endarterectomy) and caused a significant increase in left ventricular dimensions. Pre-transplant atrial septostomy caused increased left ventricular dimensions, stroke volume and cardiac index. Two patients developed post-transplant left ventricular failure. Compared with other PAH patients, they were younger (<12 years) at diagnosis, time between diagnosis and surgery lasted 2.5 times longer, left ventricular mass was smaller and pre-transplant pulmonary vascular resistance was higher. CONCLUSIONS In PAH, age at diagnosis is younger and left ventricular preload deprivation lasts longer than that in chronic thromboembolic pulmonary hypertension. Together with lower residual pulmonary vascular resistance and higher increases in preload, this might explain left ventricular failure after lung transplantation. Pre-transplant atrial septostomy might prevent post-transplant left ventricular failure
Lung transplantation in the third millennium( Book )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Monitorage de l'inflammation pulmonaire par le monoxyde de carbone endogène exhalé dans un modèle de poumons humains : Application lors d'optimisation de greffons en perfusion pulmonaire Ex-Vivo avant transplantation pulmonaire. Étude BreathDiag-COe by Vivien Brenckmann( )

1 edition published in 2020 in French and held by 1 WorldCat member library worldwide

Pour pallier au manque de greffons pulmonaires, des techniques de perfusion pulmonaire ex-vivo (PPEV) ont été développées. Les critères d'évaluation sont basés sur les paramètres physiologiques comme la qualité des échanges gazeux, les résistances vasculaires pulmonaires, la formation d'œdème, et l'aspect général des poumons.La production endogène de monoxyde de carbone (CO) est influencée par les phénomènes inflammatoires et est plus particulièrement en lien avec les mécanismes d'ischémie-reperfusion.La mesure du CO exhalé (COe) est possible grâce à un spectromètre laser (ProCeas®). Cet appareil est précis (concentrations inférieures au Ppmv) et rapide permettant un monitorage cycle à cycle, en temps réel.Le but de l'étude était d'évaluer le taux de COe des greffons pulmonaires humains en cours de procédure de PPEV et de le comparer à l'acceptation des greffons, aux autres paramètres testés et au devenir à court terme des receveurs.Matériel et méthodeDes greffons pulmonaires ont été optimisés et évalués en PPEV normothermique. Les poumons étaient progressivement réchauffés, perfusés et ventilés. S'en suivait une phase d'évaluation (incluant des manœuvres de recrutement) durant deux à quatre heures.Le ProCeas® était connecté en dérivation sur le circuit ventilatoire. La production de CO était moyennée sur cinq minutes à la fin de chaque phase de recrutement.En fin de procédure de PPEV, la décision de transplanter les poumons était prise selon les critères habituels de l'équipe chirurgicale sans avoir connaissance des valeurs de COe .Résultats et Discussion21 procédures de PPEV ont eu lieux à l'hôpital Foch de Suresnes de Décembre 2018 à Juillet 2019, dont 13 greffons à « critères élargis » (CE) et 8 issus de donneurs après arrêt cardiaque (de la catégorie III de Maastricht) (DDAC-M3).La présence de sang dans les voies aériennes faussait les résultats de COe, ainsi trois procédures ont été exclues.Il n'y avait pas de différence de COe en fonction de l'origine CE ou DDAC-M3 des poumons.Sur les 18 greffons, deux ont été définitivement récusés à la greffe. Il y avait une tendance à un COe plus élevé pour les poumons récusés (p=0,068). Cette tendance était présente dès le début des procédures.Concernant les paramètres physiologiques testés lors des procédures de PPEV, le COe était corrélé à la consommation de glucose (r=0,64 ; p=0,04) et à la production de lactates (r=0,53 ; p= 0,025). Il y avait une relation non significative avec les résistances vasculaires (p = 0,062). Il n'y avait pas de lien entre COe et formation d'œdème ni avec le rapport PaO2/FiO2 per PPEV.Concernant les données post-opératoires, en séparant les greffons en 2 groupes (COe bas Vs COe élevé, limite fixée à 0,235 Ppmv), il y avait une tendance à de meilleures capacités d'hématose (PaO2/FiO2) à 24h (p=0,052) pour ceux ayant un taux de COe bas. Tous les poumons avec taux de COe élevé ont présenté un score DPG à 3 dans les 72h (p=0,088). Il y avait également une tendance à es durées plus longues de réanimation (6 jours (+-3,25) Vs 15 jours (+-3,83), p=0,06) et de durée totale en unité de soins continus (réanimation + soins intensifs) (14,5 jours (+-2,34) vs 19 jours (+-3,4) (p=0,07)) pour les greffons avec un taux de COe élevé.ConclusionLe taux de COe per PPEV pourrait être une aide supplémentaire et précoce dans l'évaluation des poumons. Il semble pouvoir également apporter une aide pronostique pour anticiper les soins de réanimation post opératoires
Multicentric evaluation of the impact of central tumour location when comparing rates of N1 upstaging in patients undergoing video-assisted and open surgery for clinical Stage I non-small-cell lung cancer( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract OBJECTIVES Large retrospective series have indicated lower rates of cN0 to pN1 nodal upstaging after video-assisted thoracic surgery (VATS) compared with open resections for Stage I non-small-cell lung cancer (NSCLC). The objective of our multicentre study was to investigate whether the presumed lower rate of N1 upstaging after VATS disappears after correction for central tumour location in a multivariable analysis. METHODS Consecutive patients operated for PET-CT based clinical Stage I NSCLC were selected from prospectively managed surgical databases in 11 European centres. Central tumour location was defined as contact with bronchovascular structures on computer tomography and/or visibility on standard bronchoscopy. RESULTS Eight hundred and ninety-five patients underwent pulmonary resection by VATS (n = 699, 9% conversions) or an open technique (n = 196) in 2014. Incidence of nodal pN1 and pN2 upstaging was 8% and 7% after VATS and 15% and 6% after open surgery, respectively. pN1 was found in 27% of patients with central tumours. Less central tumours were operated on by VATS compared with the open technique (12% vs 28%, P <0.001). Logistic regression analysis showed that only tumour location had a significant impact on N1 upstaging (OR 6.2, confidence interval 3.6-10.8; P <0.001) and that the effect of surgical technique (VATS versus open surgery) was no longer significant when accounting for tumour location. CONCLUSIONS A quarter of patients with central clinical Stage I NSCLC was upstaged to pN1 at resection. Central tumour location was the only independent factor associated with N1 upstaging, undermining the evidence for lower N1 upstaging after VATS resections. Studies investigating N1 upstaging after VATS compared with open surgery should be interpreted with caution due to possible selection bias, i.e. relatively more central tumours in the open group with a higher chance of N1 upstaging
Short- and Long-term Outcomes After Lung Transplantation From Circulatory-Dead Donors( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract : Background: Donation after cardiac death (DCD) to overcome the donor organ shortage is well accepted in the clinical setting, although long-term outcome after DCD lung transplantation (LTx) remains largely unknown. Methods: In this retrospective study, DCD LTx recipients (n = 59) were compared with a cohort of donation after brain death (DBD) LTx recipients (n = 331) transplanted between February 2007 and September 2013; follow-up was until January 1, 2016. Short-term (duration of mechanical ventilation, intensive care unit stay, hospital stay, and highest primary graft dysfunction score within 72 hours) and long-term (chronic lung allograft dysfunction-free and overall survival) follow-up were compared over a median follow-up of 50.5 (±3.7) months for DCD and 66.8 (±1.5) months for DBD. Results: There were no differences between groups with regard to patient characteristics: age (P = 0.78), underlying disease (P = 0.30) and type of type of LTx (P = 0.10), except sex where more males were transplanted with a DCD donor (62.7%) vs (48.3%, P = 0.048). There was no difference in time on mechanical ventilation (P = 0.59), intensive care unit stay (P = 0.74), highest primary graft dysfunction score (P = 0.67) and hospital stay (P = 0.99). Moreover, chronic lung allograft dysfunction-free (P = 0.86) and overall survival (P = 0.15) did not differ between the DBD and DCD groups. Conclusions: In our experience, both short- and long-term outcomes in DCD lung recipients are comparable to that of DBD lung recipients. Therefore, DCD LTx can be considered a safe strategy that significantly increased our transplant activity. Abstract : Both short- and long-term outcome in donation after cardiac death (DCD) lung recipients is comparable to that of donation after brain-death lung recipients and DCD lung transplantation can be considered a safe strategy that significantly increased our transplant activity
Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Background: Severe primary graft dysfunction (PGD) of grade 3 (PGD3) is a common serious complication following lung transplantation. We aimed to assess physiological donor lung preservation using the Organ Care System (OCS) Lung device compared with cold static storage. Methods: In this non-inferiority, randomised, controlled, open-label, phase 3 trial (INSPIRE) recipients were aged 18 years or older and were registered as standard criteria primary double lung transplant candidates. Eligible donors were younger than 65 years old with a ratio of partial pressure of oxygen in arterial blood to the fraction of inspired oxygen of more than 300 mm Hg. Transplant recipients were randomly assigned (1:1) with permuted blocks, stratified by centre, to receive standard criteria donor lungs preserved in the OCS Lung device (OCS arm) or cold storage at 4°C (control arm). The composite primary effectiveness endpoint was absence of PGD3 within the first 72 h after transplant and 30-day survival in the per-protocol population, with a stringent 4% non-inferiority margin. Superiority was tested upon meeting non-inferiority. The primary safety endpoint was the mean number of lung graft-related serious adverse events within 30 days of transplant. We did analyses in the per-protocol and intention-to-treat populations. This trial is registered withClinicalTrials.gov, numberNCT01630434 . Findings: Between Nov 17, 2011, and Nov 24, 2014, we randomly assigned 370 patients, and 320 (86%) underwent transplantation (n=151 OCS and n=169 control); follow-up was completed in Nov 24, 2016. The primary endpoint was met in 112 (79·4%) of 141 patients (95% CI 71·8 to 85·8) in the OCS group compared with 116 (70·3%) of 165 patients (62·7 to 77·2) in the control group (non-inferiority point estimate −9·1%; 95% CI −∞ to −1·0; p=0·0038; and superiority test p=0·068). Patient survival at day 30 post-transplant was 135 (95·7%) of 141 patients (95% CI 91·0-98·4) in the OCS group and 165 patients (100%; 97·8-100·0) in the control group (p=0·0090) and at 12 months was 126 (89·4%) of 141 patients (83·1-93·9) for the OCS group compared with 146 (88·1%) of 165 patients (81·8-92·8) for the control group. Incidence of PGD3 within 72 h was reported in 25 (17·7%) of 141 patients in the OCS group (95% CI 11·8 to 25·1) and 49 (29·7%) of 165 patients in the control group (22·8 to 37·3; superiority test p=0·015). The primary safety endpoint was met (0·23 lung graft-related serious adverse events in the OCS group compared with 0·28 events in the control group [point estimate −0·045%; 95% CI −∞ to 0·047; non-inferiority test p=0·020]). In the intention-to-treat population, causes of death at 30 days and in hospital were lung graft failure or lung infection (n=2 for OCS vs n=7 for control), cardiac causes (n=4 vs n=1), vascular or stroke (n=3 vs n=0), metabolic coma (n=0 vs n=2), and generalised sepsis (n=0 vs n=1). Interpretation: The INSPIRE trial met its primary effectiveness and safety endpoints. Although no short-term survival benefit was reported, further research is needed to see whether the reduced incidence of PGD3 within 72 h of a transplant might translate into earlier recovery and improved long-term outcomes after lung transplantation. Funding: TransMedics Inc
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.94 (from 0.82 for Lung trans ... to 0.97 for Intérêt ...)

Languages